Oppenheimer Maintains Outperform on Immunocore Hldgs, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Justin Kim maintains an Outperform rating on Immunocore Hldgs (NASDAQ:IMCR) and raises the price target from $72 to $75.
August 11, 2023 | 3:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Justin Kim maintains an Outperform rating on Immunocore Hldgs and raises the price target from $72 to $75.
The raised price target by Oppenheimer indicates a positive outlook for Immunocore Hldgs. This could potentially lead to an increase in the stock price in the short term as it signals the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100